Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

MicroStrategy raises $130M daily in 2025, thriving despite Bitcoin market stress and dividend concerns.

Market News
13 Jun 2026
Blockonomi
View Source
Bullish
pluang ai news

MicroStrategy is raising over $130 million daily in 2025, marking its highest-ever capital-raising pace amid Bitcoin market challenges. Historical Bitcoin data suggests strong future returns, with median 12-month gains of 133% from current price levels. Even under a severe stress test with a compressed market valuation, MicroStrategy's preferred dividend obligations would cause only minimal stock dilution, supported by its massive monthly trading volume of $54.79 billion. This financial resilience positions MicroStrategy to not only survive but thrive through the Bitcoin bear market, making concerns about its sustainability less convincing for long-term investors.

More News

US depends fully on imports for 16 minerals, raising national security risks and investment opportunities.

US depends fully on imports for 16 minerals, raising national security risks and investment opportunities.

The US government has identified 16 minerals it produces none of, making the country 100% reliant on imports for these critical materials, which poses national security and economic risks. Financial expert Jim Rickards highlights this dependency, esp...

Market News
Bullish
1 hour ago
US and Iran likely to sign peace deal within 24 hours, ending months of conflict and easing energy tensions.

US and Iran likely to sign peace deal within 24 hours, ending months of conflict and easing energy tensions.

The US and Iran are expected to finalize a peace agreement within 24 hours, potentially ending over three months of conflict that disrupted global energy supplies and raised gasoline prices. Pakistan's Prime Minister Shehbaz Sharif announced preparat...

Market News
Neutral
3 hours ago
Epcoritamab shows high response rates in elderly diffuse large B-cell lymphoma patients in new trials.

Epcoritamab shows high response rates in elderly diffuse large B-cell lymphoma patients in new trials.

Genmab announced positive Phase 2 and Phase 1b/2 trial results for epcoritamab, a T-cell engaging antibody, in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are ineligible for standard chemotherapy. The Phase 2 trial...

Company Fundamentals
Bullish
3 hours ago
XRP tests $1.13 support amid $1.43B ETF inflows, with risks of further decline and consolidation.

XRP tests $1.13 support amid $1.43B ETF inflows, with risks of further decline and consolidation.

XRP is trading near a critical support level of $1.13 while institutional ETF inflows have surpassed $1.43 billion, signaling strong institutional interest despite retail hesitation. Analysts warn of potential downside risks and an extended consolida...

Technical Signals
Neutral
4 hours ago
Venice AI's VVV token jumps 13% after US bans Anthropic's AI models, highlighting decentralized AI demand.

Venice AI's VVV token jumps 13% after US bans Anthropic's AI models, highlighting decentralized AI demand.

The US government ordered Anthropic to suspend access to its Claude Fable 5 and Mythos 5 AI models just three days after their launch, citing export controls. In response, Venice AI's native token VVV surged over 13% in 24 hours, as the platform prom...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App